Sativa Investments has unique position in the UK market
By in

Sativa Investments has unique position in the UK market

Sativa Investments PLC’s Geremy Thomas tells Proactive that the medicinal cannabis market has seen explosive growth all over the world, particularly in Vancouver, Canada.

He adds that Sativa has a unique position in the UK market that allows UK investors to benefit from companies in regulated markets.

Read the full article here

Watch the full video interview with CEO Geremy Thomas.

Rapid Dose Therapeutics
By in

Rapid Dose Therapeutics

Rapid Dose Therapeutics, RDT, is a Canadian bio-technology company which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes.

Formed because of a recognized need to move drug delivery to a new level. RDT provides product innovation, production, and consultation to the pharmaceutical and healthcare manufacturing industry.

RDT Technology

Proprietary oral fast-dissolving drug delivery system, QuickStrip™, rapidly releases an expansive list of pharmaceuticals, emulsified oils, and a host of over-the-counter medicines. This permits API’s to enter the blood stream through a rapid dose pathway without being degraded or modified by first pass metabolism in the liver.

How rapid is a Rapid Dose Therapeutic? Studies show the QuickStrip™ technology delivery mimics blood concentrations over time to intravenous injection.

Sublingual and transmucosal transport of active molecules result from the rapid dissolution of QuickStrip™ combined with the proprietary technology.

By in ,

Sativa invests C$ 0.2 million in Canadian-based Rapid Dose Therapeutics Inc

Press Release                                                                                                                                                          23 May 2018

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa invests C$ 0.2 million in Canadian-based Rapid Dose Therapeutics Inc. which owns QuickStrip™ oral technology for medicinal cannabis use

 

Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, has subscribed to, through a private placement which may or may not precede an IPO, 400,000 shares at C$ 0.50 per share, at a cost of C$ 0.2 million cash, in Toronto-based Pharma-Tech company, Rapid Dose Therapeutics Inc. (“RDT”). 

RDT has its own patent-pending proprietary QuickStrip™ technology, a fast-dissolving strip that is placed on or under the tongue, or inside the cheek, then enters directly in to the recipient’s system, mimicking an injection path.  Pharmaceuticals, emulsified oils and over-the-counter medicines are used in RDT’s proprietary RDMx mixture technology, which is sold across North America.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said:  “RDT’s technology delivers medicinal cannabis bypassing the normal oral or inhaler delivery and, as such, is an exceptional way of ingesting the therapy, is easy to administer, provides a consistent and rapid dose, and is likely to improve patient outcomes.

“The dynamic medicinal cannabis market in Canada has allowed RDT to develop this CBD product to be absorbed directly in to a person’s system.”

Mark Upsdell, Chief Executive Officer of Rapid Dose Therapeutics, said: “Our proprietary formulation for the mixture of various medicines and pharmaceuticals to be administered through our QuickStrip™ technology, has led to RDT using CBD medicinal cannabis in QuickStrip™. 

“We are delighted to have entered in to this new relationship with Sativa.  RDT looks forward working together with Sativa in this fast developing market to unlock the potential for our products in the UK and Europe.”

–  Ends  –

For more information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

 

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativagroup.co.uk/

Veritas Pharma
By in

Veritas Pharma

Veritas Pharma Inc. is an emerging global pharmaceutical company based out of Vancouver, Canada that’s investing in the discovery, product development and commercialization of effective, patented cannabis therapies that target disease conditions in the areas of chronic pain, senior long-term care and palliative care.

Through its subsidiary company, Cannevert Therapeutics Ltd., it aims to obtain comprehensive scientific evidence, for health care professionals and patients so that they can utilize these strains with confidence of a reliable therapeutic effect.   Cannevert is made up of a strong management team, bringing together veteran academic pharmacologists, anesthetists and chemists, and each contributing to the critical need for preclinical and clinical data to support medical cannabis claims.  It also has a Health Canada Dealer License, enabling it to import cannabis products from any part of the World as well as produce extracts for sell to Canadian licensed producers and aboard through an export permit.  This allows Veritas to establish and promote globally the Cannevert brand of cannabis-based medicines.

Veritas’ investment in partnerships such as 3 Carbon Extractions Inc. and BioCan Technologies Inc., will enable it to codevelop cannabis extracts and delivery devices using not only Cannevert’s proprietary cannabis strains for upcoming clinical trials but also create newer strains that can address more unmet medical needs.

Veritas Pharma is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

By in ,

Sativa Investments commits to C$ 0.2 million investment in Canadian-based Veritas Pharma

Press Release                                                                                                                 21st May 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

(“Sativa” or “the Company”)

Sativa Investments commits to C$ 0.2 million investment in Canadian-based Veritas Pharma

Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, has subscribed for 500,000 new shares at C$ 0.40 per share, at a cost of C$ 0.2 million cash, in Canadian-based emerging global pharmaceutical company Veritas Pharma Inc (or “Veritas Pharma”), which is tri-listed on the Canadian Securities Exchange, America’s OTC exchange and the Frankfurt Stock Exchange.

Veritas Pharma focuses on the discovery, product development and commercialisation of effective patented Medicinal Cannabis therapies which target disease conditions in the areas of chronic pain, senior long-term and palliative care.

Veritas, through its subsidiary company, Cannevert Therapeutics Ltd., aims to obtain compelling scientific evidence for healthcare professionals to utilise medicinal cannabis strains with a reliable therapeutic effect on patients.

Geremy Thomas, founder and Chief Executive Officer of Sativa, said: “We are delighted to increase our portfolio of investments by, in this case, adding a pharmaceutical research and development business. Veritas Pharma is a well-respected company in the medicinal cannabis sector with an excellent pipeline for the development of strains to treat unmet clinical needs, and is a highly suitable investment.”

“The investment in Veritas reflects the Company’s strategy to invest in well-established companies in jurisdictions where the use of Medicinal Cannabis is regulatory accepted. Canada approved the use of medicinal cannabis in 2001.”

Dr. Lui Franciosi, Chief Executive of Veritas Pharma, said: “We are delighted to work together with Sativa, as we meet its investment strategy with also the potential for Veritas to have Sativa as a partner for European expansion.”

 

– Ends –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

 

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.

For more information on Sativa Investments, please visit: https://sativagroup.co.uk/